13:05 EDT Arvinas (ARVN) trading resumes
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Arvinas announces FDA approval of VEPPANU for ESR1m, ER+/HER2- ABC
- Arvinas trading halted, news pending
- Arvinas Buy Rating Driven by Robust ARV-102 LRRK2 Degrader Data and Clear Neurodegeneration Development Path
- Balanced View on Arvinas: Early Promise of ARV-102 Offset by Clinical, Safety, and Competitive Uncertainties Supporting a Hold Rating
- Arvinas price target raised to $21 from $18 at Citi